It's Time to Remind About Travere Therapeutics
The time has come to remind that the U.S. FDA is reviewing Travere Therapeutics’ (TVTX) New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for IgA Nephritis (IgAN).
We remind that the FDA has assigned a Prescription Drug User Fee Act (
This content is for paid subscribers.
Trick or Trade
February 2, 2023